Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review
International Ophthalmology · 2023
DOI: 10.1007/s10792-023-02853-5 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Ophthalmology, 2023. Verfasst von Ainhoa Gomez-Lumbreras und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30S 2000E, Salt Lake City, UT, 84112, USA. Ainhoa.Gomez-Lumbreras@pharm.utah.…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Macular Degeneration. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Pharmacological treatments for age-related macular degeneration (ArMD) include anti-vascular endothelial growth factor therapies. Bevacizumab is used off-label, as it has no indication for ArMD. This study aims to identify and describe literature on real-world evidence of bevacizumab (originator or biosimilars) use in ArMD. METHODS: A scoping review was conducted in Medline, CINAHL and Embase databases. Studies published in English after September 2017, conducted in USA, including adults (≥ 18 years old) with ArMD who received treatment with bevacizumab for ArMD were included. The review was further limited to peer-reviewed observational studies that quantitatively analyze either clinical or patient-reported outcomes among patients treated with bevacizumab for ArMD. RESULTS: The search strategy retrieved 543 studies. After title and abstract screening, a total of 142 studies were selected for full-text review leading to a total of 12 studies qualifying for data charting. All were retrospective studies. Five (41.6%) of the studies had less than 500 eyes included in the analysis, and the rest had over a thousand eyes. All except one study reported clinical outcomes (visual acuity was the main outcome in 8 (66.6%) studies). There were 3 (25%) studies reporting adverse events of bevacizumab intravitreal injections. None of the studies specified using biosimilars for bevacizumab and none mentioned patient-reported outcomes. CONCLUSION: The lack of studies aiming to study the patient-reported outcomes as well as the use of biosimilars of bevacizumab in ArMD makes this field a potential for future research. The different exposures and times to follow-up make it difficult to compare results among the selected studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30S 2000E, Salt Lake City, UT, 84112, USA. Ainhoa.Gomez-Lumbreras@pharm.utah.edu.
- Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30S 2000E, Salt Lake City, UT, 84112, USA.
- University of Utah Health Plans, Murray, UT, USA.
- ZS, 2535 West Hillcrest Drive Suite 100, Thousand Oaks, CA, 91320, USA.
- Department of Health Policy and Organization, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
- Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, VA, USA.
Zitieren
APA
Gomez-Lumbreras, A., Ghule, P., Panchal, R., Giannouchos, T., Lockhart, C. M., & Brixner, D. (2023). Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review. International Ophthalmology. https://doi.org/10.1007/s10792-023-02853-5
Vancouver
Gomez-Lumbreras A, Ghule P, Panchal R, Giannouchos T, Lockhart CM, Brixner D. Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review. International Ophthalmology. 2023. doi:10.1007/s10792-023-02853-5
BibTeX
@article{GomezLumbreras2023,
author = {Gomez-Lumbreras, Ainhoa and Ghule, Priyanka and Panchal, Rupesh and Giannouchos, Theodoros and Lockhart, Catherine M and Brixner, Diana},
title = {Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review},
journal = {International Ophthalmology},
year = {2023},
doi = {10.1007/s10792-023-02853-5}
}
EUVIMED